Journal Article

Progression of <i>Pneumocystis jiroveci</i> Pneumonia in Patients Receiving Echinocandin Therapy

Mini Kamboj, David Weinstock and Kent A. Sepkowitz

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 43, issue 9, pages e92-e94
Published in print November 2006 | ISSN: 1058-4838
Published online November 2006 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/508282
Progression of Pneumocystis jiroveci Pneumonia in Patients Receiving Echinocandin Therapy

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Echinocandins are a novel class of antifungal drugs that target β (1, 3)-D-glucan synthesis. Animal studies have shown that these agents have activity against Pneumocystis jiroveci infection; however, clinical data are lacking. We reviewed all cases of proven P. jiroveci pneumonia (PCP) in non–human immunodeficiency virus-infected patients at our hospital over a 5 year period (2001–2005). Two patients received conventional PCP treatment and concomitant use of echinocandins for presumed invasive aspergillus. In both cases, PCP progressed, and the patient died. The use of echinocandins in the prevention or treatment of PCP cannot be recommended without evidence to support their effectiveness.

Journal Article.  1946 words. 

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.